Ensysce Biosciences

Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of solutions for severe pain relief while reducing the fear of and the potential for misuse and overdose. The firm's Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms are in the process of developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. The company was founded in April 2003 and is headquartered in La Jolla, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

~ Dr. Lynn Kirkpatrick, CEO, to Introduce Satellite Symposium on Severe Pain and Next Generation Solutions ~ SAN DIEGO, CA / ACCESSWIRE / August 14, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced that the company will host a luncheon symposium and present their recent clinical data at PAINWeek on September 7-8, 2023 in Las Vegas, NV. PAINWeek is the leading conference in the world dedicated to helping pain physicians and practitioners improve their clinical knowledge and results.

Ensysce Biosciences to Present Clinical Dataset at Major PAINWeek Scientific Symposium

~ Progression Toward Full Phase 3 Evaluation of PF614 with Recently Announced IRB Approval of Key Study Protocol ~ SAN DIEGO, CA / ACCESSWIRE / August 11, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today reported financial results for the second quarter of 2023. Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, commented, "The recently announced IRB approval of the PF614-201 protocol gives us confidence in the momentum we have achieved to date, bringing us closer to our Phase 3 evaluation of PF614.

Ensysce Biosciences Reports Second Quarter 2023 Financial Results

~ Approval of Study Represents Progression Toward Full Phase 3 Evaluation of PF614 ~ ~ Study to Assess PF614 Time of Onset for Severe Pain Relief ~ SAN DIEGO, CA / ACCESSWIRE / August 8, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced the Investigational Review Board ("IRB") approval of PF614-201 protocol, ‘A Randomized, Double-Blind, Placebo-Controlled Crossover Study of PF614 on Analgesic Response in the Cold Pressor Test in Healthy Male Subjects.' The study will be conducted at Dr. Vince Clinical Research (DVCR) in Overland Park, Kansas, and is designed to confirm time of onset for pain relief by PF614.

Ensysce Biosciences Announces IRB Approval of Key Study Protocol

Engagement to aid expansion of the use of TAAP and MPAR® as well as the rapid development and commercialization of Ensysce's next generation opioids SAN DIEGO, CA / ACCESSWIRE / July 26, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced it has engaged Alacrita Consulting ("Alacrita"), a pharma and biotech consulting firm with extensive subject-matter expertise for the purpose of exploring partnering and licensing opportunities for its TAPP and MPAR® platforms and products. Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce commented, "We are pleased to be working with Alacrita and its team of highly experienced experts to explore opportunities to aid our growth and development.

Ensysce Biosciences Announces Engagement of Alacrita Consulting

Featured Presentation on ‘Development of a Multi-Pill Abuse Resistant Extended-Release Formulation to Prevent Opioid Overdose' SAN DIEGO, CA / ACCESSWIRE / June 27, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced that the company will be providing a poster presentation at the upcoming CRS (Controlled Release Society) 2023 Annual Meeting & Expo, titled ‘Development of a Multi-Pill Abuse Resistant Extended-Release Formulation to Prevent Opioid Overdose.' Chief Medical Officer, Dr. William Schmidt, will participate in the event, being held from July 24-July 28, 2023, at the Paris Hotel in Las Vegas, Nevada.

Ensysce Biosciences and Quotient Sciences to Present MPAR(R) Overdose Protection Platform at Upcoming CRS 2023 Annual Meeting and Expo

SAN DIEGO, CA / ACCESSWIRE / June 13, 2023 / Ensysce Biosciences, Inc. (the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced that it has received notice from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has demonstrated compliance with the equity requirement in Listing Rule 5550(b)(1), as described in the Hearing Panel's ("Panel") decision dated February 14, 2023, as amended. As a result, Ensysce common stock will continue trading on Nasdaq's Capital Market tier.

Ensysce Biosciences Regains Compliance with Nasdaq

SAN DIEGO, CA / ACCESSWIRE / June 7, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced an updated investor presentation has been posted to the Company's investor relations website. The updated investor presentation reflects updated financials and Company milestones as of today.

Ensysce Biosciences Releases Updated Investor Presentation Available Via Investor Relations Website

Chief Medical Officer, Dr. William Schmidt, to Present at the CPDD 85th Annual Scientific Meeting Chief Commercial Officer, Geoff Birkett, to Present Opening Address at EPHMRA 2023 Annual Conference SAN DIEGO, CA / ACCESSWIRE / June 6, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced two upcoming presentations in June. Chief Medical Officer, Dr. Bill Schmidt, will present in The College on Problems of Drug Dependence (CPDD) 85th Annual Scientific Meeting in Denver, CO, on June 17-21, 2023, and Geoff Birkett, the Company's Chief Commercial Officer, will present the opening address at the European Pharmaceutical Market Research Association (EPHMRA) Annual Conference in London on June 27-29, 2023.

Ensysce Biosciences to Participate in Upcoming Industry Events

Recently Completed Successful Ground-Breaking Study on Overdose Protection Recently Completed $7 Million Public Offering SAN DIEGO, CA / ACCESSWIRE / May 15, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today reported financial results for the first quarter of 2023 following the recently completed, successful PF614-MPAR-101 study. Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, commented, "As evident in our recently announced completion of PF614-MPAR-101, a clinical study examining the Company's first pain medication with overdose protection, PF614-MPAR, we remain focused on advancing our lead products.

Ensysce Biosciences Reports First Quarter 2023 Financial Results

SAN DIEGO, CA / ACCESSWIRE / May 12, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, announced today the closing of the previously announced public offering of an aggregate of 1,800,876 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-1 warrants to purchase up to 1,800,876 shares of common stock and Series A-2 warrants to purchase 1,800,876 shares of common stock, at a combined public offering price of $3.887 per share (or pre-funded warrant in lieu thereof) and accompanying warrants. The Series A-1 warrants have an exercise price of $3.637 per share, are exercisable immediately upon issuance and will expire five years from the date of issuance, and the Series A-2 warrants have an exercise price of $3.637 per share, are exercisable immediately upon issuance and will expire eighteen months from the date of issuance.

Ensysce Biosciences, Inc. Announces Closing of $7 Million Public Offering

SAN DIEGO, CA / ACCESSWIRE / May 10, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, announced today announced the pricing of a public offering of an aggregate of 1,800,876 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-1 warrants to purchase up to 1,800,876 shares of common stock and Series A-2 warrants to purchase 1,800,876 shares of common stock, at a combined public offering price of $3.887 per share (or pre-funded warrant in lieu thereof) and accompanying warrants. The Series A-1 warrants will have an exercise price of $3.637 per share, will be exercisable immediately upon issuance and will expire five years from the date of issuance, and the Series A-2 warrants will have an exercise price of $3.637 per share, will be exercisable immediately upon issuance and will expire eighteen months from the date of issuance.

Ensysce Biosciences, Inc. Announces Pricing of $7 Million Public Offering

Clinical-stage biotechnology firm Ensysce Biosciences (NASDAQ: ENSC ) skyrocketed sharply on Tuesday, with shares at one point gaining 50% before settling to around 26% up. Management announced the completion of its opioid-based pain medication integrated with a novel overdose protection mechanism.

Why Is Ensysce Biosciences (ENSC) Stock Up 50% Today?

~ Represents Major Milestone Towards Launch of PF614-MPAR ~ ~ PF614-MPAR on Track to be the First Drug to Protect Against Overdose ~ SAN DIEGO, CA / ACCESSWIRE / May 9, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC), clinical-stage biotech company applying transformative chemistry to improve prescription drug safety, today announced completion of PF614-MPAR-101, a clinical study examining the Company's first pain medication with overdose protection, PF614-MPAR. The final Part B of the study examined dose escalation of PF614-MPAR from 25 to 200 mg (1 to 8 dose units) and showed that PF614-MPAR successfully reduced opioid delivery when three or more doses are consumed simultaneously.

Ensysce Biosciences Announces Successful Completion of Ground-Breaking Study on Overdose Protection

~ Global QUOTIENT LIFE SCIENCES Webinar Today, April 19, 2023 at 11:30am ET ~ SAN DIEGO, CA / ACCESSWIRE / April 19, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced the Company's CEO, Dr. Lynn Kirkpatrick will be participating in ‘Strategies for Achieving Regulatory Milestones Faster: An Ensysce Biosciences & Quotient Sciences Customer Case Study Demonstrating the Benefits of an Integrated Approach for Accelerating Development' today, April 19 2023, at 11:30am ET as a featured speaker. Ensysce Biosciences' PF614-MPAR is a novel opioid combination product for the potential treatment of chronic pain that is designed to prevent both abuse and overdose.

Ensysce CEO Dr. Lynn Kirkpatrick To Present Featured Case Study of MPAR Overdose Protection Platform Accelerated Development

~ Reminder: Corporate Update Conference Call to be Held Today at 11:00am ET ~ SAN DIEGO, CA / ACCESSWIRE / April 11, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety, today announced an updated investor presentation has been posted to the Company's investor relations website. As a reminder, the Company will be holding a corporate update conference call today, Tuesday, April 11, 2023, at 11:00am ET.

Ensysce Biosciences Announces Updated Investor Presentation Available Via Investor Relations Website

~ Reduced Drug Liking of PF614 versus Oxycodone ~ SAN DIEGO, CA / ACCESSWIRE / April 3, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), today announced positive results from a key study on the oral human abuse potential of PF614, a potential next generation pain medicine. The study met all key endpoints and showed PF614 had significantly lower scores of "Drug Liking" than the oxycodone comparator at both the low and mid doses studied.

Ensysce Biosciences Announces Positive Results from Oral Human Abuse Potential Trial for PF614

~ Corporate Update Call to be Held Tuesday, April 11, 2023 ~ SAN DIEGO, CA / ACCESSWIRE / March 30, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety, today reported financial results for the fourth quarter and full year of 2022. Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, commented, "Our focus remains on execution and advancing clinical development plans for our programs that provide strong pain relief using our PF614 and PF614-MPAR drug products.

Ensysce Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results

~ Data Demonstrates Exceptional Safety Profile of PF614-MPAR, the Industry's First Overdose Protection Pain Product ~ SAN DIEGO, CA / ACCESSWIRE / March 22, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety, today announced the completion of enrollment in the final stage of the Phase 1 study, PF614-MPAR-101. This study was conducted by Dr. Maria Bermudez MD, at Quotient Sciences, Miami, Florida.

Ensysce Biosciences Announces Completion of Enrollment for Groundbreaking Opioid Overdose Protection Study

~ Ensysce Biosciences and Quotient Sciences Showcase a Unique Collaboration ~ SAN DIEGO, CA / ACCESSWIRE / March 6, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced Dr. Lynn Kirkpatrick, Chief Executive Officer, is a featured speaker at a lunch seminar on March 22, 2023 in New York sponsored by partner Quotient Sciences. The Seminar "Strategies for Achieving Regulatory Milestones Faster: An Ensysce Biosciences & Quotient Sciences customer case study demonstrating the benefits of an integrated approach for accelerating development" is taking place in tandem with Drug, Chemical & Associated Technologies Association (DCAT) Week.

Dr. Lynn Kirkpatrick, Featured Speaker to Discuss Ensysce Overdose Protection Platform at DCAT Seminar

Company Remains on Track to Report Results the End of March SAN DIEGO, CA / ACCESSWIRE / February 28, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced the database lock on February 24, 2023 for the oral Human Abuse Potential (HAP) study of PF614. PF614 is a TAAP™ (Trypsin Activated Abuse Protection) product to treat severe pain.

Ensysce Biosciences Announces Critical Step in Human Abuse Potential Study of PF614 With Database Lock

Answers Recently Asked Questions SAN DIEGO, CA / ACCESSWIRE / February 23, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today issued a letter to shareholders from Chief Executive Officer, Dr. Lynn Kirkpatrick, to address the Company's most recent frequently asked questions. Dear Fellow Shareholders, As a clinical stage biotech company working through clinical development, our opportunities to touch base with our investor community are largely tied to Company milestones and the announcement of associated clinical data.

Ensysce Biosciences Provides Corporate Update

SAN DIEGO, CA / ACCESSWIRE / February 14, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced a Poster Presentation will be presented by Geoff Birkett, Chief Commercial Officer of Ensysce, at the Annual NIH HEAL Meeting on February 22, 2023, in Washington, D.C. The HEAL initiative is an effort to improve prevention and treatment strategies for opioid misuse and addiction and to enhance pain management across NIH institutes.

Ensysce Biosciences to Present its Overdose Protection Program at the 4th Annual NIH 'HELPING END ADDICTION LONG-TERM' (HEAL) Meeting

SAN DIEGO, CA / ACCESSWIRE / February 7, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that it has closed its previously announced registered direct offering for the purchase and sale of 3,571,431 shares of the Company's common stock at a purchase price of $0.84 per share of common stock in a registered direct offering priced at-the-market under NASDAQ rules. In addition, in a concurrent private placement, the Company issued warrants to purchase up to 3,571,431 shares of common stock.

Ensysce Biosciences, Inc. Announces Closing of $3.0 Million Registered Direct Offering Priced at-the-Market Under NASDAQ Rules

SAN DIEGO, CA / ACCESSWIRE / February 3, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that it has entered into a definitive agreement for the purchase and sale of 3,571,431 shares of the Company's common stock at a purchase price of $0.84 per share of common stock in a registered direct offering priced at-the-marked under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue warrants to purchase up to 3,571,431 shares of common stock.

Ensysce Biosciences, Inc. Announces $3 Million Registered Direct Offering

SAN DIEGO, CA / ACCESSWIRE / February 1, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that its Board of Directors has declared a dividend of 0.001 of a share of newly-designated Series A Preferred Stock, par value $0.0001 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on February 13, 2023.

News for Ensysce Biosciences Stock (ENSC)